Agimexpharm Pharmaceutical Joint Stock Co
UUPCOM:AGP30,300.00
VND
+300.00
(+1.00%)
Agimexpharm Pharmaceutical Joint Stock Co
UPCOM:AGP
(Unlisted Public Company Market)
Recent
price
30,300.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Agimexpharm Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical manufacturing and distribution enterprise engaged in the development, production, marketing, wholesale, and export of finished pharmaceutical formulations, traditional herbal remedies, and dietary supplements. The company operates across three primary business segments: Prescription and Over-the-Counter Pharmaceuticals, Herbal and Traditional Medicines, and Healthcare and Nutrition Products. Its core product portfolio encompasses a comprehensive range of therapeutic categories, including antibacterial and antibiotic formulations comprising cephalosporins, penicillins, fluoroquinolones, and macrolides; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; cardiovascular, antihypertensive, and lipid-lowering treatments; metabolic and antidiabetic agents; gastrointestinal medications, antacids, and proton pump inhibitors; respiratory therapies, antihistamines, and mucolytics; central nervous system and neurological preparations; topical dermatological solutions and ointments; traditional herbal remedies and plant-based phytopharmaceuticals; and dietary supplements, multivitamins, and nutritional wellness formulations. Agimexpharm manufactures these products in diverse dosage forms, including film-coated tablets, hard gelatin capsules, softgels, effervescent tablets, oral suspensions, dry syrups, powders, granules, and topical liquids. In addition to finished pharmaceutical manufacturing, the company provides contract manufacturing services, pharmaceutical research and formulation development, quality control testing, and wholesale distribution of medical consumables and healthcare equipment. The company serves public and private hospitals, clinical centers, medical institutions, wholesale distributors, and retail pharmacy chains across Vietnam, while also exporting select pharmaceutical lines to international markets throughout Southeast Asia, including Cambodia, Laos, and Myanmar. Originally established in 1981 as a state-owned pharmaceutical enterprise and equitized in 2004, Agimexpharm Pharmaceutical Joint Stock Company is headquartered in Long Xuyen City, An Giang Province, Vietnam, and trades on the UPCoM exchange under the ticker AGP. In recent operational and strategic developments, Agimexpharm has advanced the construction and commissioning of its modern high-technology pharmaceutical manufacturing complex in the Binh Hoa Industrial Park, developed in alignment with EU-GMP and PIC/S standards to expand international export capacity and qualify for high-tier domestic hospital tenders. Furthermore, the company has expanded its commercial partnerships with major national retail pharmacy networks, accelerated bioequivalence testing programs across core generic cardiovascular and metabolic product lines to replace imported therapeutics, and completed automated production upgrades and quality control modernizations across its manufacturing facilities.